AWSensors, is coordinating the European project LIQBIOPSENS to develop
liquid biopsy technologies for the early detection of colorectal cancer.
The new system will allow quick and easy cancer detection and
monitoring at a third of the cost of existing, typically invasive,
procedures.
The Spanish company AWSensors has developed technology for a high-sensitivity molecular detection system for use in cancer
screening. It is based on a technique known as liquid biopsy: the
analysis of small fluid samples, like blood or saliva, making it
completely non-invasive. It is also fast, giving results within the
hour. When combined with genomic analysis, it will be possible to obtain
reliable early diagnoses and devise precision medicine approaches to
cancer treatment.The new system will be tested on the blood samples of colorectal cancer
patients over the next three years. This cancer is the second cause of
death in Europe and one of the most common, alongside breast, lung and
prostate cancers.
The current go-to method for reliable cancer diagnosis is tumor
tissue biopsy, but this method is invasive, painful and expensive. It
also only provides information of a single point in the evolution of the
disease. The new system also has the advantage of being up to three
times cheaper than other real-time methods, such as quantitative PCR,
and can be carried out by non-specialists.
LiqBiopSens will therefore enable simple, inexpensive, non-invasive screening for early detection and periodic monitoring of tumors.
No comments:
Post a Comment